Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2007
12/31/2006
12/31/2005
12/31/2004
12/27/2003
Revenue
0
0
0
1
1
1
Revenue Growth (YoY)
--
--
-100%
0%
0%
-75%
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
11
12
17
8
2
0
Research & Development
23
25
24
19
11
4
Operating Expenses
34
37
41
27
13
5
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
-35
-37
-38
-59
-12
-4
Income Tax Expense
0
0
0
0
0
0
Net Income
-35
-37
-38
-59
-13
-5
Net Income Growth
-3%
-3%
-36%
354%
160%
-75%
Shares Outstanding (Diluted)
53.64
53.14
50.52
34.42
0.96
0.4
Shares Change (YoY)
0%
5%
47%
3,478%
139%
25%
EPS (Diluted)
-0.66
-0.7
-0.75
-1.71
-14.51
-13
EPS Growth
-4%
-7%
-56%
-88%
12%
-79%
Free Cash Flow
-31
-31
-30
-21
-9
-3
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
-2,600%
-1,100%
-400%
Profit Margin
0%
0%
0%
-5,900%
-1,300%
-500%
Free Cash Flow Margin
0%
0%
0%
-2,100%
-900%
-300%
EBITDA
-34
-37
-41
-26
-11
-4
EBITDA Margin
0%
0%
0%
-2,600%
-1,100%
-400%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-34
-37
-41
-26
-11
-4
EBIT Margin
0%
0%
0%
-2,600%
-1,100%
-400%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Panacos Pharmaceuticals Inc's key financial statements?
According to the latest financial statement (Form-10K), Panacos Pharmaceuticals Inc has a total asset of $55, Net loss of $-37
What are the key financial ratios for PANC?
Panacos Pharmaceuticals Inc's Current ratio is 2.11, has a Net margin is 0, sales per share of $0.
How is Panacos Pharmaceuticals Inc's revenue broken down by segment or geography?
Panacos Pharmaceuticals Inc largest revenue segment is Broadcast Advertising, at a revenue of 94,228,000 in the most earnings release.For geography, United States is the primary market for Panacos Pharmaceuticals Inc, at a revenue of 112,773,000.
Is Panacos Pharmaceuticals Inc profitable?
no, according to the latest financial statements, Panacos Pharmaceuticals Inc has a net loss of $-37
Does Panacos Pharmaceuticals Inc have any liabilities?
yes, Panacos Pharmaceuticals Inc has liability of 26
How many outstanding shares for Panacos Pharmaceuticals Inc?
Panacos Pharmaceuticals Inc has a total outstanding shares of 53.54